{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T23:42:38Z","timestamp":1779320558058,"version":"3.51.4"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2018,4,21]],"date-time":"2018-04-21T00:00:00Z","timestamp":1524268800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1007\/s00520-018-4196-z","type":"journal-article","created":{"date-parts":[[2018,4,21]],"date-time":"2018-04-21T01:34:42Z","timestamp":1524274482000},"page":"3441-3446","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Reality of the emetogenic level of irinotecan"],"prefix":"10.1007","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5570-154X","authenticated-orcid":false,"given":"Maria-Angeles","family":"Garcia-del-Barrio","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvador","family":"Martin-Algarra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Azucena","family":"Aldaz Pastor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,4,21]]},"reference":[{"key":"4196_CR1","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1634\/theoncologist.4-3-191","volume":"4","author":"PJ Hesketh","year":"1999","unstructured":"Hesketh PJ (1999) Defining the emetogenicity of cancer chemotherapy regimens: relevance to clinical practice. Oncologist 4:191\u2013196","journal-title":"Oncologist"},{"key":"4196_CR2","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1007\/s00520-004-0718-y","volume":"13","author":"SM Grunberg","year":"2005","unstructured":"Grunberg SM, Osoba D, Hesketh PJ, Gralla RJ, Borjeson S, Rapoport BL, du Bois A, Tonato M (2005) Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity\u2014an update. Support Care Cancer 13:80\u201384","journal-title":"Support Care Cancer"},{"key":"4196_CR3","doi-asserted-by":"publisher","first-page":"S232","DOI":"10.1093\/annonc\/mdq194","volume":"21","author":"F Roila","year":"2010","unstructured":"Roila F, Herrstedt J, Aapro M et al (2010) Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol 21:S232\u2013S243","journal-title":"Ann Oncol"},{"key":"4196_CR4","doi-asserted-by":"publisher","first-page":"4189","DOI":"10.1200\/JCO.2010.34.4614","volume":"29","author":"E Basch","year":"2011","unstructured":"Basch E, Prestrud AA, Hesketh PJ, American Society of Clinical Oncology et al (2011) Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 29:4189\u20134198","journal-title":"J Clin Oncol"},{"key":"4196_CR5","doi-asserted-by":"publisher","first-page":"S43","DOI":"10.1007\/s00520-010-1003-x","volume":"19","author":"S Grunberg","year":"2011","unstructured":"Grunberg S, Warr D, Gralla R et al (2011) Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity\u2014state of the art. Support Care Cancer 19:S43\u2013S47","journal-title":"Support Care Cancer"},{"key":"4196_CR6","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s00520-016-3332-x","volume":"25","author":"K Jordan","year":"2017","unstructured":"Jordan K, Chan A, Gralla R et al (2017) 2016 updated MASCC\/ESMO consensus recommendations: emetic risk classification and evaluation of the emetogenicity of antineoplastic agents. Support Care Cancer 25:271\u2013275","journal-title":"Support Care Cancer"},{"key":"4196_CR7","doi-asserted-by":"publisher","first-page":"883","DOI":"10.6004\/jnccn.2017.0117","volume":"15","author":"MJ Berger","year":"2017","unstructured":"Berger MJ, Ettinger DS, Aston J, Barbour S, Bergsbaken J, Bierman PJ, Brandt D, Dolan DE, Ellis G, Kim EJ, Kirkegaard S, Kloth DD, Lagman R, Lim D, Loprinzi C, Ma CX, Maurer V, Michaud LB, Nabell LM, Noonan K, Roeland E, Rugo HS, Schwartzberg LS, Scullion B, Timoney J, Todaro B, Urba SG, Shead DA, Hughes M (2017) NCCN guidelines insights: antiemesis, version 2.2017. J Natl Compr Cancer Netw 15:883\u2013893","journal-title":"J Natl Compr Cancer Netw"},{"key":"4196_CR8","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1093\/annonc\/mdv138","volume":"26","author":"K Jordan","year":"2015","unstructured":"Jordan K, Jahn F, Aapro M (2015) Recent developments in the prevention of chemotherapy-induced nausea and vomiting (CINV): a comprehensive review. Ann Oncol 26:1081\u20131090","journal-title":"Ann Oncol"},{"key":"4196_CR9","unstructured":"MAT\u2014MASCC antiemesis tool. Available at http:\/\/www.mascc.org\/mat"},{"key":"4196_CR10","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.jpainsymman.2006.10.018","volume":"34","author":"A Molassiotis","year":"2007","unstructured":"Molassiotis A, Coventry PA, Stricker CT, Clements C, Eaby B, Velders L, Rittenberg C, Gralla RJ (2007) Validation and psychometric assessment of a short clinical scale to measure chemotherapy-induced nausea and vomiting: the MASCC antiemesis tool. J Pain Symptom Manag 34:148\u2013159","journal-title":"J Pain Symptom Manag"},{"key":"4196_CR11","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1007\/s00520-003-0482-4","volume":"11","author":"A Martin","year":"2003","unstructured":"Martin A, Pearson J, Cai B, Elmer M, Horgan K, Lindley C (2003) Assessing the impact of chemotherapy-induced nausea and vomiting on patients\u2019 daily lives: a modified version of the Functional Living Index-Emesis (FLIE) with 5-day recall. Support Care Cancer 11:522\u2013527","journal-title":"Support Care Cancer"},{"key":"4196_CR12","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1111\/j.1600-0447.1983.tb09716.x","volume":"67","author":"AS Zigmond","year":"1983","unstructured":"Zigmond AS, Snaith RP (1983) The hospital anxiety and depression scale. Acta Psychiat Scand 67:361\u2013370","journal-title":"Acta Psychiat Scand"},{"key":"4196_CR13","first-page":"1","volume":"7","author":"G Dranitsaris","year":"2009","unstructured":"Dranitsaris G, Joy A, Young S et al (2009) Identifying patients at high risk for nausea and vomiting after chemotherapy: development of a practical prediction tool I. Acute nausea and vomiting. J Support Oncol 7:1\u20138","journal-title":"J Support Oncol"},{"key":"4196_CR14","first-page":"9","volume":"7","author":"T Petrella","year":"2009","unstructured":"Petrella T, Clemons M, Joy A et al (2009) Identifying patients at high risk for nausea and vomiting after chemotherapy: the development of a practical validated prediction tool II. Delayed nausea and vomiting. J Support Oncol 7:9\u201316","journal-title":"J Support Oncol"},{"key":"4196_CR15","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1177\/107815529900500303","volume":"5","author":"A Junker","year":"1999","unstructured":"Junker A, Wiedemann G (1999) Antiemetic guidelines: a cooperation between a non-university hospital (Klinikum Remscheid) and a university center (Medical University of L\u00fcbeck) in Germany. J Oncol Pharm Pract 5:125\u2013127","journal-title":"J Oncol Pharm Pract"},{"key":"4196_CR16","doi-asserted-by":"publisher","first-page":"2759","DOI":"10.1007\/s00520-013-1843-2","volume":"21","author":"A Molassiotis","year":"2013","unstructured":"Molassiotis A, Stamataki Z, Kontopantelis E (2013) Development and preliminary validation of a risk prediction model for chemotherapy-related nausea and vomiting. Support Care Cancer 21:2759\u20132767","journal-title":"Support Care Cancer"},{"key":"4196_CR17","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1093\/annonc\/mdx100","volume":"28","author":"G Dranitsaris","year":"2017","unstructured":"Dranitsaris G, Molassiotis A, Clemons M, Roeland E, Schwartzberg L, Dielenseger P, Jordan K, Young A, Aapro M (2017) The development of a prediction tool to identify cancer patients at high risk for chemotherapy-induced nausea and vomiting. Ann Oncol 28:1260\u20131267","journal-title":"Ann Oncol"},{"key":"4196_CR18","doi-asserted-by":"publisher","first-page":"2955","DOI":"10.1007\/s00520-013-1944-y","volume":"21","author":"N Silvestris","year":"2013","unstructured":"Silvestris N, Brunetti AE, Russano N, Narduli P (2013) Optimal control of nausea and vomiting with a three-drug antiemetic regimen with aprepitant in metastatic pancreatic cancer patients treated with first-line modified FOLFIRINOX. Support Care Cancer 21:2955\u20132956","journal-title":"Support Care Cancer"},{"key":"4196_CR19","unstructured":"Grunberg S, Jatoi A, Navari R & Strasser F (2012) Domino effect: nausea and vomiting in cancer (CME\/CE Released: 7\/27\/2012). http:\/\/www.medscape.org\/viewarticle\/767820"},{"key":"4196_CR20","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1007\/s00520-009-0723-2","volume":"18","author":"JA Roscoe","year":"2010","unstructured":"Roscoe JA, Morrow GR, Colagiuri B, Heckler CE, Pudlo BD, Colman L, Hoelzer K, Jacobs A (2010) Insight in the prediction of chemotherapy-induced nausea. Support Care Cancer 18:869\u2013876","journal-title":"Support Care Cancer"},{"key":"4196_CR21","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.1007\/s00520-010-1036-1","volume":"19","author":"I Olver","year":"2011","unstructured":"Olver I, Molassiotis A, Aapro M et al (2011) Antiemetic research: future directions. Support Care Cancer 19:S49\u2013S55","journal-title":"Support Care Cancer"},{"key":"4196_CR22","doi-asserted-by":"crossref","first-page":"S19622","DOI":"10.1200\/jco.2007.25.18_suppl.19622","volume":"25","author":"J Nieva","year":"2007","unstructured":"Nieva J, Webb W, Siuzdak G (2007) Pharmacokinetic effect of aprepitant on irinotecan in patients with colorectal cancer. J Clin Oncol 25:S19622","journal-title":"J Clin Oncol"},{"key":"4196_CR23","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.autneu.2006.07.009","volume":"129","author":"G Sanger","year":"2006","unstructured":"Sanger G, Andrews P (2006) Treatment of nausea and vomiting: gaps in our knowledge. Auton Neurosci 129:3\u201316","journal-title":"Auton Neurosci"},{"key":"4196_CR24","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1007\/s00520-004-0662-x","volume":"12","author":"A Glaus","year":"2004","unstructured":"Glaus A, Knipping C, Morant R, B\u00f6hme C, Lebert B, Beldermann F, Glawogger B, Ortega PF, H\u00fcsler A, Deuson R (2004) Chemotherapy-induced nausea and vomiting in routine practice: a European perspective. Support Care Cancer 12:708\u2013715","journal-title":"Support Care Cancer"},{"key":"4196_CR25","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s00520-006-0109-7","volume":"15","author":"E Ballatori","year":"2007","unstructured":"Ballatori E, Roila F, Ruggeri B, Betti M, Sarti S, Soru G, Cruciani G, di Maio M, Andrea B, Deuson RR (2007) The impact of chemotherapy-induced nausea and vomiting on health-related quality of life. Support Care Cancer 15:179\u2013185","journal-title":"Support Care Cancer"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-018-4196-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-018-4196-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-018-4196-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T03:33:27Z","timestamp":1604201607000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-018-4196-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,21]]},"references-count":25,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["4196"],"URL":"https:\/\/doi.org\/10.1007\/s00520-018-4196-z","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,21]]},"assertion":[{"value":"28 June 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The Ethics Committee of Clinical Research (ECCR) of Navarra approved the study in May 2012.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}